Delaware
|
001-32325
|
13-3894575
|
|
(State
or other jurisdiction of
incorporation
or organization)
|
(Commission
File
Number)
|
(IRS
Employer Identification
No.)
|
|
420
Lexington Avenue, Suite 1609
|
|||
New
York, New York
10170
|
|||
(Address
of principal executive offices)
|
o
|
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
(c)
|
Exhibits.
|
||
10.1
|
Amendment
dated October 19, 2005 to the Employment Agreement dated
as of June 13,
2003 by and between Callisto Pharmaceuticals, Inc. and
Gary S.
Jacob.
|
||
10.2
|
Amendment
dated October 19, 2005 to the Employment Agreement dated as
of September
23, 2003, as amended April 6, 2004 by and between Callisto
Pharmaceuticals, Inc. and Donald H. Picker.
|
||
10.3
|
Amendment
dated October 19, 2005 to the Employment Agreement dated as of
March 28,
2005 by and between Callisto Pharmaceuticals, Inc. and Pamela
Harris.
|
||
10.4
|
Amendment
dated October 19, 2005 to the Employment Agreement dated as of
January 15,
2004 by and between Callisto Pharmaceuticals, Inc. and Bernard
Denoyer.
|
||
10.5
|
Amendment
dated October 19, 2005 to the Employment Agreement dated as of
April 6,
2004 by and between Synergy Pharmaceuticals Inc. and Kunwar
Shailubhai.
|
CALLISTO PHARMACEUTICALS, INC. | ||
|
|
|
By: | /s/ Gary S. Jacob | |
|
||
Gary
S. Jacob, Ph.D.
Chief
Executive Officer
|